Choice of antiepileptic drugs for the elderly: Possible drug interactions and adverse effects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 1, 2012, Pages 81-91

  Jankovic, Slobodan M ^a   Dostic, Milivoje ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Adverse drug reactions; Antiepileptic drugs; Elderly; Interactions

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAPENEM; CLONAZEPAM; ERTAPENEM; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LOPINAVIR; MEROPENEM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RITONAVIR; THIAZIDE DIURETIC AGENT; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANOREXIA; APLASTIC ANEMIA; ATAXIA; ATTENTION DISTURBANCE; CLOSED ANGLE GLAUCOMA; CREATININE BLOOD LEVEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ECTOPIC HORMONE PRODUCTION; ELDERLY CARE; EPILEPSY; EPILEPTIC STATE; FRACTURE; HEART DISEASE; HEART FAILURE; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INFECTION; LIVER NECROSIS; LOADING DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; OBSESSION; PERIPHERAL EDEMA; PRESCRIPTION; PRURITUS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THROMBOCYTOPENIA; WALKING DIFFICULTY; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CARDIOVASCULAR DISEASES; CHOICE BEHAVIOR; DRUG INTERACTIONS; EPILEPSY; HUMANS; PIRACETAM;

EID: 84255171153     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.645535     Document Type: Review

References (96)

1. Ossemann M, Bruls E, de Borchgrave V, et al. Guidelines for the management of epilepsy in the elderly. Acta Neurol Belg 2006;8:111-16 (Pubitemid 44613870)
2. Sander JW, Hart YM, Johnson AL, Shorvon SD. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990;336:1267-71 (Pubitemid 20382979)
3. Hopwood MJ. Psychotropic medication use in older people. J Pharm Pract Res 2007;37:153-6 (Pubitemid 47123061)
4. Johnell K, Fastbom J. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1 300 000 older people. Eur J Clin Pharmacol 2011; Epub ahead of print
5. Gomez-Pavon J, Gonzalez Garcia P, Frances Roman I, et al. Recommendations for the prevention of adverse drug reactions in older adults with dementia. Rev Esp Geriatr Gerontol 2010;45:89-96
6. Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology 2009;110:1176-81
7. Harms SL, Eberly LE, Garrard JM, et al. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. J Am Geriatr Soc 2005;53:1023-8 (Pubitemid 41647602)
8. Arain AM, Abou-Khalil BW. Management of new-onset epilepsy in the elderly. Nat Rev Neurol 2009;5:363-71
9. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007;24:377-83 (Pubitemid 46452398)
10. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9 (Pubitemid 46763258)
11. Stefan H, Hubbertz L, Peglau I, et al. Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand 2008;118:164-74
12. Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging 2010;5:89-99
13. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7 (Pubitemid 29413167)
14. Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007;48:1292-302 (Pubitemid 47063092)
15. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-8 (Pubitemid 24074484)
16. Valentini S, Arbaizar-Rodriguez P, Abarca-Costalago M, et al. Severe hyponatremia by oxcarbazepine in an elderly. Rev Neurol 2009;48:614-15
17. Gumbrevicius G, Sveikata A. A case of severe hyponatremia in a patient suffering from epilepsy and using oxcarbazepine. Medicina (Kaunas) 2006;42:649-52
18. Dogan EA, Usta BE, Bilgen R, et al. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav 2008;13:156-61
19. Ortenzi A, Paggi A, Foschi N, et al. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy. Funct Neurol 2008;23:97-100
20. Kutluay E, McCague K, DSouza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-80 (Pubitemid 37184590)
21. Chaudhry MM, Abrar M, Mutahir K, Mendoza C. Oxcarbazepine-induced hemolytic anemia in a geriatric patient. Am J Ther 2008;15:187-9 (Pubitemid 351450786)
22. Mahmud J, Mathews M, Verma S, Basil B. Oxcarbazepine-induced thrombocytopenia. Psychosomatics 2006;47:73-4 (Pubitemid 43017125)
23. Evans BK, Kustra RP, Hammer AE. Assessment of tolerability in elderly patients: changing to lamotrigine therapy. Am J Geriatr Pharmacother 2007;5:112-19 (Pubitemid 47264114)
24. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-73 (Pubitemid 40800699)
25. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994;35:381-90 (Pubitemid 24138826)
26. Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001;42:764-71 (Pubitemid 32605939)
27. VanCott AC, Cramer JA, Copeland LA, et al. Suicide-related behaviors in older patients with new anti epileptic drug use: data from the VA hospital system. BMC Med 2010;8:4
28. Kemp DE, Gilmer WS, Fleck J, Dago PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectr 2007;12:106-11
29. York RC, Coleridge ST. Cardiopulmonary arrest following intravenous phenytoin loading. Am J Emerg Med 1988;6:255-9
30. Bedichek E, Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med 1991;151:2297-8
31. Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med 2006;30:75-9 (Pubitemid 43129882)
32. Fattouch J, Di Bonaventura C, Casciato S, et al. Intravenous levetiracetam as first-line treatment of status epilepticus in the elderly. Acta Neurol Scand 2010; 121:418-21
33. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: Comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011;52:1292-6
34. Hofler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011; Epub ahead of print
35. Erdogan G, Ceyhan D, Gulec S. Possible heart failure associated with pregabalin use: case report. Agri 2011;23:80-3
36. Page RL II, Cantu M, Lindenfeld J, et al. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown) 2008;9:922-5
37. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. JAMA 1998;280:1837-42 (Pubitemid 28544424)
38. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in elderly patients. Pharmacoepidemiol Pharmacokinet Arch Fam Med 1994;3:589-98
39. Jette N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011;68:107-12
40. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001;15:633-42 (Pubitemid 32848344)
41. Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011;52:1884-9
42. Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66:1318-24 (Pubitemid 43739637)
43. Perreault S, Dragomir A, Blais L, et al. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf 2008;17:248-59 (Pubitemid 351404036)
44. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med 2004;71(Suppl 2):S42-8 (Pubitemid 41830287)
45. Fife TD, Blum D, Fisher RS. Measuring the effects of antiepileptic medications on balance in older people. Epilepsy Res 2006;70:103-9 (Pubitemid 44209223)
46. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9 (Pubitemid 28007514)
47. ONeil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996;46:1457-9 (Pubitemid 26159315)
48. No authors listed Acute liver failure linked to felbamate use. Am J Hosp Pharm 1994;51:2882-7
49. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39(Suppl 7):S8-16 (Pubitemid 28485582)
50. Pugh MJ, Vancott AC, Steinman MA, et al. Choice of initial antiepileptic drug for older veterans: possible pharmacokinetic drug interactions with existing medications. Am Geriatr Soc 2010;58:465-71
51. Van der Lee MJ, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006;80:159-68 (Pubitemid 44160694)
52. Mueller TH, Beeber AR. Delirium from valproic acid with lamotrigine. Am J Psychiatry 2004;161:1128-9
53. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996;18:523-31 (Pubitemid 26330471)
54. Burneo JG, Limdi N, Kuzniecky RI, et al. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology 2003;60:1991-2 (Pubitemid 36736021)
55. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000;55:588-91 (Pubitemid 30647265)
56. Banfield CR, Zhu GR, Jen JF, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit 1996;18:19-29 (Pubitemid 26033354)
57. Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989;30:225-9 (Pubitemid 19095114)
58. Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia 1999;40:1122-8 (Pubitemid 29372628)
59. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80 (Pubitemid 26276948)
60. Mack CJ, Kuc S, Mulcrone SA, et al. Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience. Seizure 2002;11:464-7 (Pubitemid 35203595)
61. Vucicevic K, Miljkovic B, Pokrajac M, et al. The influence of drug-drug interaction and patients characteristics on valproic acids clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci 2009;38:512-18
62. Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther 2008;33:513-19
63. Birnbaum AK, Ahn JE, Brundage RC, et al. Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 2007;29:571-5 (Pubitemid 47494054)
64. Gu J, Huang Y. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. Am J Geriatr Pharmacother 2009;7:26-33
65. Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther 2006;31:393-6 (Pubitemid 44060205)
66. Cabanes Mariscal MA, Sanchez Lopez P, Alvarez Herranz P, Chamorro Merino G. Pharmacokinetic interaction between valproic acid and ertapenem. Farm Hosp 2006;30:313-15 (Pubitemid 46102056)
67. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005;64:1-11 (Pubitemid 40726160)
68. Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 2003;44:171-8 (Pubitemid 36206018)
69. Gustavson LE, Cato A III, Boellner SW, et al. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther 1998;5:9-16 (Pubitemid 28079301)
70. Gustavson LE, Sommerville KW, Boellner SW, et al. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Am J Ther 1998;5:73-9 (Pubitemid 28152904)
71. Thomsen MS, Groes L, Agers H, Kruse T. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol 1998;38:1051-6 (Pubitemid 28524453)
72. Ragueneau-Majlessi I, Levy RH, Bergen D, et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res 2004;62:1-11 (Pubitemid 39424186)
73. Levy RH, Ragueneau-Majlessi I, Garnett WR, et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol 2004;44:1230-4 (Pubitemid 39391481)
74. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13
75. Almeida L, Nunes T, Sicard E, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010;121:257-64
76. Nunes T, Sicard E, Almeida L, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010;26:1355-62
77. Gidal B, Anderson G. Epilepsy in the elderly: special pharmacotherapeutic considerations. Consult Pharm 1998;1:62-74
78. Koyama H, Sugioka N, Uno A, et al. Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol 1999;51:1009-14; 70 (Pubitemid 29462387)
79. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003;20:141-52 (Pubitemid 36246296)
80. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-9 (Pubitemid 14068498)
81. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004;62(5 Suppl 2):S24-9 (Pubitemid 38298935)
82. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998;18:273-81 (Pubitemid 28145143)
83. Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbitone levels in epileptic patients. Br J Clin Pharmacol 1977;4:541-7 (Pubitemid 8161091)
84. Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 2002;22:329-64 (Pubitemid 34205171)
85. Punyawudho B, Ramsay RE, Macias FM, et al. Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 2008;48:455-63 (Pubitemid 351389112)
86. Milovanovic JR, Jankovic SM. Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 2009;47:752-60
87. May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2007;29:789-94 (Pubitemid 350190856)
88. Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997;44:129-34 (Pubitemid 27327063)
89. Posner J, Holdich T, Chrome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-8
90. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76 (Pubitemid 23232410)
91. Doose DR, Larsson KL, Natarajan J, et al. Comparative single-dose pharmacokinetics of topiramate in elderly versus young men and women. Epilepsia 1998;39(Suppl 6):56
92. Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011;13:346-54
93. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002;22:27-39 (Pubitemid 34792768)
94. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81 (Pubitemid 36876104)
95. Leppik IE, Birnbaum AK. Epilepsy in the elderly. Ann NY Acad Sci 2010;1184:208-24
96. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res 2006;68(Suppl 1):S49-63 (Pubitemid 43143413)